Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 5 Carcinoma, Hepatocellular 4 Rectal Neoplasms 2 Neoplasms 2 Gastrointestinal Stromal Tumors 2 Solid Malignant Tumors 1 Sarcoma, Ewing 1 Sarcoma 1 Recurrence 1 Piebaldism 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Osteosarcoma 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Meningioma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 HER2 IHC3+ Advanced Colorectal Cancer 1 Glioblastoma 1 Disease Progression 1 Cholangiocarcinoma 1 Bone Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 5 lutetium Lu 177 dotatate 4 Specimen Handling 4 Radiosurgery 3 gallium Ga 68 dotatate 2 Ga(III)-DOTATOC 2 Bevacizumab 2 regorafenib 1 pembrolizumab 1 olaparib 1 neratinib 1 capivasertib 1 cabozantinib 1 brigatinib 1 abemaciclib 1 X-Rays 1 Watchful Waiting 1 Tablets 1 Surveys and Questionnaires 1 Sunitinib 1 Radiotherapy, Intensity-Modulated 1 Protons 1 Proton Therapy 1 Photons 1 Observation 1 ONC206 1 Nivolumab 1 Mental Status and Dementia Tests 1 Lysine 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Meningioma × regorafenib × 90 days × Clear all

NCT06275919 2026-05-13

MIRAGE

Istituto Oncologico Veneto IRCCS

Phase 2 Recruiting

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡